Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) May 18, 2017

	Bioptix, Inc.
	(Exact name of Registrant as specified in its charter)

Colorado		001-33675		84-155337
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

834-F South Perry Street, Suite 443 Castle Rock, CO		80104
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code:

(303) 545-5550

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On May 18, 2017, Bioptix, Inc. (the "Company") received a notice from The Nasdaq Stock Market ("Nasdaq") indicating that the Company had regained compliance with Nasdaq's audit committee requirements as set forth in Nasdaq Listing Rule 5605. The compliance was regained following the appointment of Andrew Kaplan to the Company's Board of Directors and Audit Committee as previously disclosed on May 8, 2017.

Nasdaq Listing Rule 5605 requires that the Company's audit committee be comprised of at least three independent directors. The Company's non-compliance resulted from the April 6, 2017 appointment of Mr. Michael M. Beeghley, the Company's current Chairman and then member of the audit committee, to the position of Chief Executive Officer. Mr. Beeghley's appointment to the position of Chief Executive Officer resulted in his no longer being independent, resulting in the audit committee thereupon being comprised of two independent members.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.